Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)

Osimertinib is active against T790M-positive epidermal growth factor receptor mutant non-small cell lung cancer. We enrolled 122 sensitive epidermal growth factor receptor mutant non-small cell lung cancer patients who were planned to receive or were receiving first-/second-generation epidermal grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Naka, Go, Yokoyama, Takuma, Usui, Kazuhiro, Ishida, Hiroo, Kishi, Kazuma, Uemura, Kohei, Ohashi, Yasuo, Kunitoh, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264253/
https://www.ncbi.nlm.nih.gov/pubmed/35323965
http://dx.doi.org/10.1093/jjco/hyac032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264253/
https://www.ncbi.nlm.nih.gov/pubmed/35323965
http://dx.doi.org/10.1093/jjco/hyac032

Ejemplares similares